

ATTORNEY DOCKET NO. 47234-5005-00-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shigehiko MIZUTANI)	Confirmation No.: Unassigned
)	
Application No.: NEW)	Group Art Unit: Unassigned
(National Stage of PCT Application)	
No. PCT/JP2004/013883 filed)	Examiner: Unassigned
September 15, 2004))	
)	
Filed: April 13, 2006)	
)	
For: METHOD FOR PROGNOSTIC)	
EVALUATION OF CARCINOMA USING)	
ANTI-P-LAP ANTIBODY)	

Commissioner for Patents

U.S. Patent and Trademark Office

Customer Window Mail Stop: ☒ New Application ☐ Amendment ☐ AF ☐ Issue Fee
 Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT (IDS)

☒ **Under 37 C.F.R. § 1.97(b):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. To the undersigned's knowledge, this IDS is being filed before the mailing date of a first Office Action on the merits, before the mailing date of a first Office Action on the merits after filing an RCE under § 1.114, or within three months of the application filing date.

☐ **Under 37 C.F.R. § 1.97(c):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Office Action, a Notice of Allowance, or another action that closes prosecution in the application.

☐ The fee of \$180.00 set forth in § 1.17(p) is included herein; or

☐ Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ **Under 37 C.F.R. § 1.97(d):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(c) but before payment of the issue fee.

☐ The fee of \$180.00 set forth in § 1.17(p) is included herein; and

10/575763

☐ Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☒ A search report or other listing of documents from a counterpart, related, or other application dated December 6, 2004 and having documents cited thereon is attached for the Examiner's consideration. Any of these documents not previously cited, and any additional documents are listed on the PTO Form 1449.

☒ Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. As for any document listed on the accompanying PTO-1449 that is in a language other than English, relevance can be understood from an enclosed English abstract or at least partial translation or from mention in the specification or in a search report for a corresponding application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this Application, including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required and including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0573. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

DRINKER, BIDDLE & REATH LLP

Dated: April 13, 2006


Jeffrey G. Kilian
Registration No. 50,891

CUSTOMER NO. 055694
DRINKER, BIDDLE & REATH LLP
1500 K Street, N.W., Suite 1100
Washington, D.C. 20005-1209
Tel: 202.842.8800; Fax: 202.842.8465

INFORMATION DISCLOSURE CITATION		Attorney Docket No.: 47234-5005-00-US		Serial No.: NEW 10/575763			
(Use several sheets if necessary)		Applicants Shigehiko MIZUTANI		Page 1 of 1			
PTO Form 1449		Filing Date: April 13, 2006		Group Art Unit: Unassigned			
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation YES NO
OTHER DOCUMENTS							
(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)							
		Suzuki YUKA et al. "Possible Role of Placental Leucine Aminopeptidase In The Antiproliferative Effect of Oxytocin In Human Endometrial Adenocarcinoma." <u>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</u> . Vol. 9, No. 4, April 2003.					
		Toda SHIGERU et al. "Existence of Placental Leucine Aminopeptidase/Oxytocinase/Insulin-regulated Membrane Aminopeptidase In Human Endometrial Epithelial Cells." <u>The Journal of Clinical Endocrinology and Metabolism</u> . Vol. 87, No. 3, March 2002.					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							